Ipilimumab, a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of advanced melanoma, was the first ICI that received approval, opening a new era in cancer immunotherapy [4]. Here, CTLA4 is linked to melanoma.